Figure 4.
TIL fraction in ovarian carcinoma and survival. (a) QuanTILfy was performed on primary tumors from 30 ovarian carcinoma patients with known survival outcomes, ranging from 1 to 122 months. A high degree of variability in TIL percent was observed among patients, ranging from 1 to 25%. Notably, no clonal expansion of specific T-cell populations was observed in the tumors, as each sample contained a normal distribution of TCRβ subgroups. (b) TIL fractions were averaged for tumors from patients with short-term (< 2 yrs., n = 14) and long-term survival (> 5 yrs. n = 16). A 2.5-fold higher average TIL fraction was observed for > 5 yr. survivors (two-tail unpaired t test, n=30, p = 0.0273).